Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial

Biometrical Journal

Volumn 56, Issue 6, 2014, Pages 933-946

  Huang, Bo ^a   Kuan, Pei Fen ^b  

^a PFIZER INC   (United States)

^b Stony Brook University   (United States)

Author keywords

Adaptive weight; Dose finding; MTD; Oncology; Time to event

Indexed keywords

TOXICITY;

ADAPTIVE WEIGHTS; BAYESIAN; DOSE FINDING; DOSE LIMITING TOXICITY; DROP-OUT; FIRST CYCLE; MTD; PHASE I; TIME TO EVENTS; WEIGHT FUNCTIONS;

ONCOLOGY;

MONOCLONAL ANTIBODY;

BAYES THEOREM; BIOMETRY; CALIBRATION; HUMAN; NEOPLASMS; PHASE 1 CLINICAL TRIAL (TOPIC); PROCEDURES; TIME;

ANTIBODIES, MONOCLONAL; BAYES THEOREM; BIOMETRY; CALIBRATION; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; NEOPLASMS; TIME FACTORS;

EID: 84931065384     PISSN: 03233847     EISSN: 15214036     Source Type: Journal    
DOI: 10.1002/bimj.201300261     Document Type: Article

References (20)

1. Babb, J., Rogatko, A. and Zacks, S. (1998). Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine 17, 1103-1120.
2. Bekele, B., Ji, Y., Shen, Y. and Thall, P. (2008). Monitoring late-onset toxicities in phase I trials using predictive risks. Biostatistics 9, 442-457.
3. Braun, T. M. (2006). Generalizing the TITE-CRM to adapt for early- and late-onset toxicities. Statistics in Medicine 25, 2071-2083.
4. Cheung, Y. K. (2011). Dose Finding by the Continual Reassessment Method. Taylor & Francis, Boca Raton, FL.
5. Cheung, Y. K. and Chappell, R. (2000). Sequential designs for phase I clinical trials with late onset toxicities. Biometrics 56, 1177-1182.
6. Cheung, Y. K. and Thall, P. (2002). Monitoring the rates of composite events with censored data in phase II clinical trials. Biometrics 58, 89-97.
7. Desai, S. P., Ben Josef, E., Normolle, D., Francis, I. R., Greenson, J. K., Simeone, D. M., Chang, A. E., Colletti, L. M., Lawrence, T. S. and Zalupski, M. M. (2007). Phase I study of Oxaliplatin, full dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. Journal of Clinical Oncology 25, 4587-4592.
8. Healey, D., Carlson, P., Huang, B. and Marshall, M. (2010). Clinical outcome of first-line melanoma patients who continue tremelimumab in spite of early disease progression. Journal of Clinical Oncology (Meeting Abstracts) 28, 2574.
9. Lee, S. and Cheung, Y. (2009). Model calibration in the continual reassessment method. Clinical Trials 6, 227-238.
10. Liu, S., Yin, G. and Yuan, Y. (2013). Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. The Annals of Applied Statistics 7, 2138-2156.
11. Mauguen, A., Le Deley, M. C. and Zohar, S. (2011). Dose-finding approach for dose escalation with overdose control considering incomplete observations. Statistics in Medicine 30, 1584-1594.
12. Millward, M., Underhill, C., Lobb, S., McBurnie, J., Meech, S., Gomez-Navarro, J., Marshall, M., Huang, B. and Mather, C. (2013). Phase I study of tremelimumab plus PF-3512676 in patients with melanoma or advanced solid tumors. British Journal of Cancer 108, 1998-2004.
13. Muler, J., McGinn, C., Normolle, D., Lawrence, T., Brown, D., Hejna, G. and Zalupski, M. (2004). Phase I trial using a time to event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. Journal of Clinical Oncology 22, 238-243.
14. Normolle, D. and Lawrence, T. (2006). Designing dose escalation trials with late onset toxicities using the time to event continual reassessment method. Journal of Clinical Oncology 24, 4426-4433.
15. O'Quigley, J., Pepe, M. and Fisher, L. (1990). Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46, 33-48.
16. Rogatko, A., Schoeneck, D., Jonas, W., Tighiouart, M., Khuri, F. R. and Porter, A. (2007). Translation of innovative designs into phase I trials. Journal of Clinical Oncology 25, 4982-4986.
17. Storer, B. E. (1989). Design and analysis of Phase I clinical trials. Biometrics 45, 925-937.
18. Thall, P. and Cook, J. (2004). Dose finding based on efficacy-toxicity trade-offs. Biometrics 60, 684-693.
19. Wages, N. A., Conaway, M. R. and O'Quigley, J. (2013). Using the time-to-event continual reassessment method in the presence of partial orders. Statistics in medicine 32, 131-141.
20. Yuan, Y. and Yin, G. (2011). Robust EM continual reassessment method in oncology dose finding. Journal of the American Statistical Association 104, 818-831.